HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.

Abstract
Radionuclide cineangiography was used to evaluate 32 patients who sustained long-term remission of soft tissue sarcoma after adjuvant therapy with a cumulative doxorubicin dose from 480 to 550 mg/m body surface area. Left ventricular ejection fraction at rest was below normal (less than 45%) in eight of 32 patients. The abnormal response of ejection fraction to exercise identified an additional 12 patients with diminished left ventricular functional reserve. Ejection fraction determined at rest or during exercise did not differ 1 to 9 months) and those studied 30 months (range, 21 to 43 months) after completing doxorubicin treatment. Sequential studies in 13 patients, done 6 to 15 months after initial post-doxorubicin evaluation also showed persistent depression of average ejection fraction at rest and with exercise, with the continued deterioration of left ventricular function in six patients. Left ventricular dysfunction, evident in over half of asymptomatic patients even long after "acceptable" cumulative doses of doxorubicin, may persist for years.
AuthorsJ S Gottdiener, D J Mathisen, J S Borer, R O Bonow, C E Myers, L H Barr, D E Schwartz, S L Bacharach, M V Green, S A Rosenberg
JournalAnnals of internal medicine (Ann Intern Med) Vol. 94 Issue 4 pt 1 Pg. 430-5 (Apr 1981) ISSN: 0003-4819 [Print] United States
PMID7212498 (Publication Type: Journal Article)
Chemical References
  • Doxorubicin
Topics
  • Adolescent
  • Adult
  • Aged
  • Cardiac Output (drug effects)
  • Cineangiography (methods)
  • Doxorubicin (administration & dosage, adverse effects)
  • Exercise Test
  • Female
  • Heart Rate (drug effects)
  • Heart Ventricles (diagnostic imaging, physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Sarcoma (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: